日前，武汉禾元生物科技股份有限公司（以下简称"禾元生物"）成功通过上交所科创板上市委审议。作 为科创板重启第五套上市标准后首家过会的企业，禾元生物的成功，标志着武汉生物医药产业实现了 从"实验室到临床"的科技创新与产业创新融合（以下简称"科产融合"）新跨越。 在武汉，更多创新力量正沿着科产融合的道路加速奔跑。启钠新能的生产线上，一场"元素魔术"正在上 演：磷、铁、钠等基础原材料经过精确配比，在自动化生产线上流转。研磨、喷雾干燥、高温烧结、精 密粉碎……一系列工序后，定制化的钠离子电池正极产品稳定产出。 "武汉已构建起完整的新材料产业链条，强大的产业协同能力，为初创公司提供了广阔的市场空间和无 限可能。"武汉启钠新能源科技有限公司创始人、董事长胡培表示。 武汉正以其"宽容失败、赋能梦想"的独特创新生态，吸引并转化着无数像胡培这样的青年才俊。他们从 单纯的"求职者"或"创业者"，成长为深度参与科产融合的"创新合伙人"。 "来这里，做新质生产力的定义者！来这里，做前沿产业的破局者！来这里，让你的梦想与城市共生 长！"在武汉市"建设支点当好龙头"系列形势政策宣讲之"推动科技创新和产业创新深度融合"主题报告 会上，武汉 ...

继首家之后，又有1家企业采用科创板第五套标准申报上市。 近日，生物医药企业恒润达生递交了科创板申报材料，申报书明确表示，本次申报科创板采用的是第五套上市 标准。公司产品尚未上市销售，公司尚未盈利并预期持续亏损。 业内人士认为，重启未盈利企业适用科创板第五套标准上市，有利于增强对优质科技型企业的制度包容性、适 应性，彰显尊重科技创新规律，更好支持优质科技型企业发展的政策导向。 又一家采用第五套标准申报科创板 恒润达生的招股书称，公司是一家拟采用第五套上市标准的生物医药行业公司。 公司适用并符合《上海证券交易所科创板股票上市规则》第2.1.2条规定的上市标准："预计市值不低于人民币 40亿元，主要业务或产品需经国家有关部门批准，市场空间大，目前已取得阶段性成果。医药行业企业需至少 有一项核心产品获准开展二期临床试验，其他符合科创板定位的企业须具备明显的技术优势并满足相应条 件。" "未来一段时间内，公司预期仍将存在累计未弥补亏损并持续亏损。"招股书称。 恒润达生是一家专注于突破性免疫细胞治疗产品研发与生产的创新生物医药公司，主要聚焦恶性血液病和实体 肿瘤等治疗领域。截至本招股说明书签署日，公司形成了从早期研发阶段 ...

科创板第五套上市标准重启后首家过会企业来了！ 7月1日晚，上交所上市审核委员会发布的公告显示，当天召开的上市审核委员会会议审议通过了科创板拟上市 企业武汉禾元生物科技股份有限公司（简称"禾元生物"）的发行上市申请。这是科创板第五套标准重启以来， 首家成功过会的IPO企业。 6月18日，中国证监会主席吴清在2025陆家嘴论坛上宣布，将在科创板设置科创成长层，并且重启未盈利企业 适用科创板第五套标准上市。在业内人士看来，禾元生物IPO成功过会，是落实证监会《关于在科创板设置科 创成长层 增强制度包容性适应性的意见》（以下简称"科创板深化改革'1+6 ' 政策措施"）的又一典型案例，充 分彰显了尊重科技创新规律，更好支持优质科技型企业发展的政策导向。 分享、点赞、在看 顺手三连越来越有钱 目前，科创板已有20家公司使用第五套标准上市。其中，19家为创新药研发企业，1家为高端医疗器械研发企 业。 2024年，20家第五套标准上市企业合计营业收入超过140亿元，较2023年相比增长超40%，有16家营收过1亿 元，其中4家营收超10亿元。2025年第一季度，第五套标准上市公司延续增长趋势，合计实现营业收入37.80亿 ...

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the IPO review despite three consecutive years of losses, marking a significant milestone as the first company to benefit from the reactivation of the fifth set of listing standards for unprofitable enterprises on the Sci-Tech Innovation Board [2][3]. Group 1: Company Overview - Heyuan Biotechnology was established in 2006 and focuses on innovative drug research and development, primarily generating revenue from non-core products such as research reagents, with projected revenue of 25.21 million yuan in 2024 [2]. - The company has reported losses of 144 million yuan, 187 million yuan, and 151 million yuan from 2022 to 2024, totaling over 480 million yuan in cumulative losses [2]. Group 2: Product and Technology - The core product, HY1001 (plant-derived recombinant human serum albumin injection), is a first-class new drug that has completed phase III clinical trials and is expected to be the first domestically approved recombinant human serum albumin drug, addressing the current 60% import dependency in China [3]. - The "rice blood-making" technology, which utilizes rice embryo cell expression systems, has been recognized with a national technology invention award and is seen as a unique technological pathway that combines synthetic biology and medicine [3]. Group 3: Market and Regulatory Context - The fifth set of standards for the Sci-Tech Innovation Board appears tailored for companies like Heyuan Biotechnology, requiring a minimum market value of 4 billion yuan and at least one core product approved for phase II clinical trials [3]. - The successful IPO of Heyuan Biotechnology serves as a potential model for other unprofitable enterprises in cutting-edge fields such as artificial intelligence and biomedicine [2]. Group 4: Risks and Challenges - The company faces several risks, including the need to successfully launch its core product and demonstrate its efficacy to capture the anticipated market share [4]. - Ongoing patent disputes with Ventria Bioscience may hinder international sales and could result in significant compensation costs if the company loses the case [9]. - If profitability is not achieved in the future, the quality of information disclosure and communication with investors may pose substantial challenges [9].

政策动向 和黄医药宣布小分子联合疗法在中国获批 近日，和黄医药宣布，沃瑞沙（ORPATHYS，赛沃替尼/ savolitinib）和泰瑞沙（TAGRISSO，奥希替尼/ osimertinib）的联合疗法的新药上市申请获中国国家药品监督管理局（NMPA）批准，用于治疗表皮生 长因子受体（EGFR）基因突变阳性经EGFR酪氨酸激酶抑制剂（TKI）治疗后进展的伴MET扩增的局部 晚期或转移性非鳞状非小细胞肺癌患者。 资本市场 两部门发文支持创新药高质量发展 7月1日，国家医保局召开新闻发布会介绍《支持创新药高质量发展的若干措施》。其中，从加大创新药 研发支持力度、支持创新药进入基本医保药品目录和商业健康保险创新药品目录、支持创新药临床应 用、提高创新药多元支付能力、强化保障措施等5个方面提出16条具体措施，全链条支持创新药发展。 国家医保局价采中心副主任王小宁表示，中国的创新药产业已经由引进模仿转向了创新输出，为世界提 供了守卫生命健康的中国方案。2024年，中国药企完成了超过90笔海外授权的交易，总金额超过了500 亿美元。未来，国家医保局将支持更多有条件的地区发挥区位优势，搭建创新药交易平台，加强国际推 广。 ...

Group 1: Policy Support for Innovative Drugs - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on five areas and sixteen specific measures [1] - The measures aim to create a clinical value-oriented environment for innovative drug research and development, establish a diversified payment system, and enhance the accessibility of innovative drugs [1] Group 2: Longhua High-Tech's H-Share Listing - Changchun High-Tech announced plans to issue H-shares and list on the Hong Kong Stock Exchange to deepen its global strategy and accelerate internationalization [2] - The move aligns with the trend of domestic pharmaceutical companies pursuing both domestic and international growth, potentially enhancing the company's international financing capabilities and brand image [2] Group 3: IPO Approval for He Yuan Bio - Wuhan He Yuan Bio's IPO was approved by the Shanghai Stock Exchange, marking the first company to pass under the newly restarted fifth set of listing standards for the Sci-Tech Innovation Board [3] - The company focuses on recombinant human albumin, with its core product expected to be the first recombinant human albumin drug approved in China [3] Group 4: Clinical Trial Acceptance for Microchip Bio - Microchip Bio announced that its clinical trial application for CS231295, a selective Aurora B inhibitor for advanced solid tumors, was accepted by the FDA [4] - This drug is the first of its kind to enter clinical trials globally, showcasing the company's technological strength in innovative drug development [4] Group 5: Angli Kang's Innovation Drug Pipeline - Angli Kang reported that it currently has only one innovative drug project, ALK-N001, which is in the I phase of clinical trials as of the announcement date [5][6] - The company highlighted the long cycle, high investment, and uncertainty associated with innovative drug development, which may temper market speculation [6]

Company Overview - Wuhan Heyuan Biotechnology Co., Ltd. (Heyuan Bio) is an innovative biopharmaceutical company that has developed a leading plant-based bioreactor technology platform for protein expression [1] - The company has established a proprietary rice endosperm cell bioreactor expression system, which includes upstream and downstream technologies for efficient recombinant protein expression and purification [1] Market Opportunity - The domestic market for recombinant human serum albumin (rHSA) is significant, with a market size of 25.8 billion RMB in 2020 [2] - The supply of human serum albumin drugs in China is constrained, with over 60% of the market relying on imports, indicating a strong clinical and strategic demand [2] Product Development - The core product, HY1001, has completed Phase III clinical trials, demonstrating good safety and efficacy [2] - The New Drug Application (NDA) for HY1001 is expected to be accepted by September 2024, targeting the treatment of "hypoalbuminemia due to liver cirrhosis" [2] Production Capacity - The company has established a commercial-scale production line capable of producing 10 tons of OsrHSA per year and has obtained a drug manufacturing license [2] - A new production line with a capacity of 120 tons of OsrHSA is under construction, covering an area of approximately 70,000 square meters [2] Financial Performance - Heyuan Bio reported revenues of approximately 13.4 million RMB, 24.3 million RMB, and 25.2 million RMB for the years 2022, 2023, and 2024, respectively [3] - The company incurred net losses of approximately 144 million RMB, 187 million RMB, and 151 million RMB for the same periods [3] Key Financial Metrics - Total assets as of December 31, 2024, are projected to be approximately 1.061 billion RMB, with total liabilities leading to an asset-liability ratio of 43.37% [5] - The net profit attributable to the parent company is expected to be -151.4 million RMB for 2024, with a basic and diluted earnings per share of -0.56 RMB [5]

科创板第五套上市标准重启后首家过会企业来了！ 7月1日晚，上交所上市审核委员会发布的公告显示，当天召开的上市审核委员会会议审议通过了科创板拟上市企业武汉禾元生物科技股份有限公司（简称"禾 元生物"）的发行上市申请。这是科创板第五套标准重启以来，首家成功过会的IPO企业。 6月18日，中国证监会主席吴清在2025陆家嘴论坛上宣布，将在科创板设置科创成长层，并且重启未盈利企业适用科创板第五套标准上市。在业内人士看 来，禾元生物IPO成功过会，是落实证监会《关于在科创板设置科创成长层 增强制度包容性适应性的意见》（以下简称"科创板深化改革'1+6 ' 政策措施"）的 又一典型案例，充分彰显了尊重科技创新规律，更好支持优质科技型企业发展的政策导向。 禾元生物成立于2006年，是一家创新型生物医药企业。自创立以来，该公司便将业务聚焦于"重组人白蛋白"这一蓝海赛道。据悉，禾元生物核心产品HY1001 （重组人白蛋白注射液）已完成III期临床试验，并被国家药监局纳入优先审评程序，预计将于近期获批上市，有望成为国内首个上市的重组人白蛋白药品。 目前，禾元生物收入主要来自药用辅料、科研试剂等非核心产品，核心创新药产品正在研发， ...

策源资本投资摩尔线程递交招股书 其招股说明书显示，2022年3月巴中振兴发展一号产业投资基金（有限合伙）受让富邦高投股份；2022年 5月巴中振兴将上述股份以相同价格转让给同一控制下的巴中川陕。巴中振兴基金管理人为巴中川陕革命 老区振兴发展基金管理有限公司。 川创投投资云知声港交所上市 6月30日，云知声智能科技股份有限公司港交所主板挂牌上市，成为"港股AGI第一股"。云知声成立于 2012年，在以深度学习模型发布为标志的人工智能自然语言处理取得突破后不久，推出首个基于BERT的 大语言模型UniCore，作为自己的中心技术平台云知大脑的初始核心算法模型，并为广泛的垂直行业的客 户赋能一系列AI解决方案。 成立至今，云知声获得启明创投、挚信资本、磐谷创投、中网投、京东、中电健康基金、中金、360、高 通等知名机构的投资。招股说明书显示，2017年四川省创新创业股权投资基金合伙企业（有限合伙）投 资了云知声。该基金2015年正式设立，由川创投管理，重点支持初创期、种子期及成长期的科技型中小 微企业发展。 6月30日，摩尔线程智能科技（北京）股份有限公司递交招股书准备在科创板上市。摩尔线程专注于研发 设计全功能G ...

根据上交所公告，武汉禾元生物科技股份有限公司（简称"禾元生物"）将于7月1日接受科创板上市委员会 审议。作为科创板第五套上市标准重启后的首家上会企业，禾元生物凭借"稻米造血"这一创新技术，致力 于突破关键生物制品供应瓶颈，实现重组人白蛋白的战略自主可控，为中国乃至全球创新药行业开辟了一 条绿色、高效、可持续的生产新路径，精准呼应了科创板支持"硬科技"、鼓励突破性生物医药创新的政策 导向，为更多创新药企利用资本市场实现跨越式发展提供了示范路径。 用稻米"种"出救命药，成就生物医药创新典范 人血清白蛋白 是血浆中的主要蛋白成分，俗称"黄金救命药"，被广泛应用于治疗因失血、烧伤、烫伤、外 科手术引起的循环衰竭、脑损伤等引起的脑水肿、以及肝硬化、肾病综合征等导致的低白蛋白血症等，已 成为国内临床上使用最广泛的血制品，长期占据院内药品销售额排行榜第一名。 根据弗若沙利文数据，2023年中国人血白蛋白药用市场规模达到361亿元，预计2030年市场规模达到570亿 元人民币。然而，国内60%以上的供应依赖进口，血浆采集量仅能满足不到40%的需求。 瞄准这一市场蓝海及行业痛点，禾元生物开辟了颠覆性的技术路径—— 通过水稻胚乳 ...